The two reported trials, CD70-targeting CTX130 (NCT04438083) and CD19-targeting TT52CAR19 (NCT04438083), reported no GvHD in CTX130 and a 16.7% incidence in TT52CAR19 [79, 80]. This evidence concerns the gene CD19 and graft versus host disease.